image credit: Freepik

Johnson & Johnson’s Tecvayli receives FDA approval for reduced dosing in multiple myeloma patients

February 23, 2024


The regulator’s decision means that RRMM patients who have achieved a complete response or better for at least six months can receive a 1.5mg/kg dose of the BCMA-targeting bispecific antibody every two weeks.

More than 35,000 new cases of multiple myeloma, a currently incurable blood cancer that affects a type of white blood cell called plasma cells, are expected to be diagnosed in the US this year.

Read More on PMLiVE